TY - JOUR T1 - Cardiac Ion Channel Effects of Tolterodine JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 935 LP - 940 DO - 10.1124/jpet.103.062182 VL - 308 IS - 3 AU - Jiesheng Kang AU - Xiao-Liang Chen AU - Hongge Wang AU - Junzhi Ji AU - William Reynolds AU - Sungtaek Lim AU - James Hendrix AU - David Rampe Y1 - 2004/03/01 UR - http://jpet.aspetjournals.org/content/308/3/935.abstract N2 - Tolterodine is a muscarinic antagonist widely used in the treatment of urinary incontinence. Although tolterodine has not been reported to alter cardiac repolarization, it is chemically related to other muscarinic antagonists known to prolong cardiac repolarization. For this reason, we studied the effects of tolterodine on cardiac ion channels and action potential recordings. Using patch-clamp electrophysiology, we found that tolterodine was a potent antagonist of the human ether-a-go-go-related gene (HERG) K+ channel, displaying an IC50 value of 17 nM. This potency was similar to that observed for the antiarrhythmic drug dofetilide (IC50 of 11 nM). Tolterodine block of HERG displayed a positive voltage dependence, suggesting an interaction with an activated state. Tolterodine had little effect on the human cardiac Na+ channel at concentrations of up to 1 μM. Inhibition of L-type Ca2+ currents by tolterodine was frequency-dependent with IC50 values measuring 143 and 1084 nM at 1 and 0.1 Hz, respectively. Both tolterodine and dofetilide prolonged action potential duration in single guinea pig myocytes over the concentration range of 3 to 100 nM. However, prolongation was significantly larger for dofetilide compared with tolterodine. Tolterodine seems to be an unusual drug in that it blocks HERG with high affinity, but produces little QT prolongation clinically. Low plasma levels after therapeutic doses combined with mixed ion channel effects, most notably Ca2+ channel blockade, may serve to attenuate the QT prolonging effects of this potent HERG channel antagonist. The American Society for Pharmacology and Experimental Therapeutics ER -